Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
"Sure, the trade war's taking its toll on business ... it's just not taking its toll where it was supposed to," Jim Cramer says.Mad Money with Jim Cramerread more
Joe Biden called on President Donald Trump Friday to release the transcript of a call with a foreign leader that is the subject of a whistleblower complaint. Biden described...Politicsread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Palantir Technologies is targeting a valuation of at least $26 billion in a private fundraising round, the first for the Peter Thiel-backed data analytics startup in four...Wall Streetread more
Michael Pack, a conservative filmmaker linked to Steve Bannon, saw at least $1.6 million in donations from his nonprofit sent into the coffers of his independent production...Politicsread more
The New England Patriots released Antonio Brown just 11 days after signing the wide receiver. The NFL Super Bowl champion team initially had kept him in the face of a rape...Sportsread more
Drugmaker Merck reported a better-than-expected first-quarter profit on Tuesday, helped by a more than 150 percent rise in sales of cancer drug Keytruda.
Merck is increasingly reliant on the blockbuster medicine, which is positioned to become the leading player in a new generation of oncology treatments and rival Bristol-Myers Squibb's Opdivo.
Both drugs harness the body's immune system to recognize and fight cancer cells, but last month's survival data from trials of the treatments gave Keytruda an edge over Opdivo, according to industry experts.
Keytruda raked in sales of $1.46 billion in the quarter, ahead of $1.40 billion estimated by analysts, according to Thomson Reuters.
Revenue from the drug accounted for nearly 15 percent of Merck's total sales, helped by its expanded approval to treat various forms of cancer.
Sales of Bristol-Myers Squibb's Opdivo surged 34 percent to $1.51 billion in the latest quarter.
Merck raised its full-year forecast for adjusted earnings to between $4.16 and $4.28 per share from between $4.08 and $4.23 per share estimated previously.
Net income fell 52.5 percent to $736 million, or 27 cents per share, hurt by a $1.4 billion charge related to a collaboration with Eisai Co Ltd, the company said.
Excluding items, Merck earned $1.05 per share, ahead of analysts' estimates of $1 per share .
Revenue rose 6.4 percent to $10.04 billion, but missed estimates of $10.11 billion.
Merck's shares rose 1.1 percent to $59.50 before the bell.